Monoclonal antibody to the O-side chain of Escherichia coli enhances the efficacy of cefotaxime against experimental K1 E. coli infection caused by a homologous O type

Kwang Sik Kim; Alan S. Cross; Jerald Sadoff

doi:10.1016/0888-0786(90)90032-J

Monoclonal antibody to the O-side chain of Escherichia coli enhances the efficacy of cefotaxime against experimental K1 E. coli infection caused by a homologous O type

Kwang Sik Kim, Alan S. Cross, Jerald Sadoff

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

In an effort to develop more effective therapy for neonatal K1 Escherichia coli infection, a murine hybridoma antibody to the O-side chain of E. coli lipopolysaccharides (LPS) and cefotaxime, alone and in combination, were evaluated for their therapeutic efficacy against experimental K1 E. coli infection due to a homologous O serotype in newborn rats. Infected rats received either the LPS antibody (3 mg kg^-1), cefotaxime (100 mg kg^-1 day^-1) or a combination of the two. Overall, the survival rate of animals receiving cefotaxime (46%) was significantly greater than that of animals receiving the LPS antibody alone (20%). It is of interest that the combination of cefotaxime and the LPS antibody was significantly more beneficial than either agent alone, as shown by a greater survival rate (73%). These findings suggest that immunotherapy with antibodies directed to O-LPS may be a useful adjunct to antimicrobial chemotherapy in neonatal E. coli infection.

Original language	English (US)
Pages (from-to)	95-99
Number of pages	5
Journal	Serodiagnosis and Immunotherapy in Infectious Disease
Volume	4
Issue number	2
DOIs	https://doi.org/10.1016/0888-0786(90)90032-J
State	Published - Apr 1990
Externally published	Yes

Keywords

Escherichia coli
anti-LPS antibody
immunotherapy
neonates

ASJC Scopus subject areas

Immunology
Microbiology (medical)

Access to Document

10.1016/0888-0786(90)90032-J

Cite this

Monoclonal antibody to the O-side chain of Escherichia coli enhances the efficacy of cefotaxime against experimental K1 E. coli infection caused by a homologous O type. / Kim, Kwang Sik; Cross, Alan S.; Sadoff, Jerald.
In: Serodiagnosis and Immunotherapy in Infectious Disease, Vol. 4, No. 2, 04.1990, p. 95-99.

Research output: Contribution to journal › Article › peer-review

@article{8611754ecdda4455af869806fa6f8cf3,

title = "Monoclonal antibody to the O-side chain of Escherichia coli enhances the efficacy of cefotaxime against experimental K1 E. coli infection caused by a homologous O type",

abstract = "In an effort to develop more effective therapy for neonatal K1 Escherichia coli infection, a murine hybridoma antibody to the O-side chain of E. coli lipopolysaccharides (LPS) and cefotaxime, alone and in combination, were evaluated for their therapeutic efficacy against experimental K1 E. coli infection due to a homologous O serotype in newborn rats. Infected rats received either the LPS antibody (3 mg kg-1), cefotaxime (100 mg kg-1 day-1) or a combination of the two. Overall, the survival rate of animals receiving cefotaxime (46%) was significantly greater than that of animals receiving the LPS antibody alone (20%). It is of interest that the combination of cefotaxime and the LPS antibody was significantly more beneficial than either agent alone, as shown by a greater survival rate (73%). These findings suggest that immunotherapy with antibodies directed to O-LPS may be a useful adjunct to antimicrobial chemotherapy in neonatal E. coli infection.",

keywords = "Escherichia coli, anti-LPS antibody, immunotherapy, neonates",

author = "Kim, {Kwang Sik} and Cross, {Alan S.} and Jerald Sadoff",

note = "Funding Information: This work was presented in part at the annual meeting of the Society for Pediatric Research and the American Pediatric Society, May 1985 in Washington, D.C. This work was supported by a Basic Research Grant l-1043 from the March of Dimes Birth Defects Foundation and ROl-NS-26310 from the National Institute of Neurological and Communicative Disorders and Stroke. We thank Jane Hong for her technical assistance and Caroline Rivera for typing the manuscript.",

year = "1990",

month = apr,

doi = "10.1016/0888-0786(90)90032-J",

language = "English (US)",

volume = "4",

pages = "95--99",

journal = "Serodiagnosis and Immunotherapy in Infectious Disease",

issn = "0888-0786",

publisher = "Academic Press Inc.",

number = "2",

}

TY - JOUR

T1 - Monoclonal antibody to the O-side chain of Escherichia coli enhances the efficacy of cefotaxime against experimental K1 E. coli infection caused by a homologous O type

AU - Kim, Kwang Sik

AU - Cross, Alan S.

AU - Sadoff, Jerald

N1 - Funding Information: This work was presented in part at the annual meeting of the Society for Pediatric Research and the American Pediatric Society, May 1985 in Washington, D.C. This work was supported by a Basic Research Grant l-1043 from the March of Dimes Birth Defects Foundation and ROl-NS-26310 from the National Institute of Neurological and Communicative Disorders and Stroke. We thank Jane Hong for her technical assistance and Caroline Rivera for typing the manuscript.

PY - 1990/4

Y1 - 1990/4

N2 - In an effort to develop more effective therapy for neonatal K1 Escherichia coli infection, a murine hybridoma antibody to the O-side chain of E. coli lipopolysaccharides (LPS) and cefotaxime, alone and in combination, were evaluated for their therapeutic efficacy against experimental K1 E. coli infection due to a homologous O serotype in newborn rats. Infected rats received either the LPS antibody (3 mg kg-1), cefotaxime (100 mg kg-1 day-1) or a combination of the two. Overall, the survival rate of animals receiving cefotaxime (46%) was significantly greater than that of animals receiving the LPS antibody alone (20%). It is of interest that the combination of cefotaxime and the LPS antibody was significantly more beneficial than either agent alone, as shown by a greater survival rate (73%). These findings suggest that immunotherapy with antibodies directed to O-LPS may be a useful adjunct to antimicrobial chemotherapy in neonatal E. coli infection.

AB - In an effort to develop more effective therapy for neonatal K1 Escherichia coli infection, a murine hybridoma antibody to the O-side chain of E. coli lipopolysaccharides (LPS) and cefotaxime, alone and in combination, were evaluated for their therapeutic efficacy against experimental K1 E. coli infection due to a homologous O serotype in newborn rats. Infected rats received either the LPS antibody (3 mg kg-1), cefotaxime (100 mg kg-1 day-1) or a combination of the two. Overall, the survival rate of animals receiving cefotaxime (46%) was significantly greater than that of animals receiving the LPS antibody alone (20%). It is of interest that the combination of cefotaxime and the LPS antibody was significantly more beneficial than either agent alone, as shown by a greater survival rate (73%). These findings suggest that immunotherapy with antibodies directed to O-LPS may be a useful adjunct to antimicrobial chemotherapy in neonatal E. coli infection.

KW - Escherichia coli

KW - anti-LPS antibody

KW - immunotherapy

KW - neonates

UR - http://www.scopus.com/inward/record.url?scp=0025180268&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025180268&partnerID=8YFLogxK

U2 - 10.1016/0888-0786(90)90032-J

DO - 10.1016/0888-0786(90)90032-J

M3 - Article

AN - SCOPUS:0025180268

SN - 0888-0786

VL - 4

SP - 95

EP - 99

JO - Serodiagnosis and Immunotherapy in Infectious Disease

JF - Serodiagnosis and Immunotherapy in Infectious Disease

IS - 2

ER -

Monoclonal antibody to the O-side chain of Escherichia coli enhances the efficacy of cefotaxime against experimental K1 E. coli infection caused by a homologous O type

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this